Elder Pharmaceuticals and Enzymotec Sign commercial Agreement to Sell CardiaBeat(TM) in the Indian Market

Indian Pharmaceutical company Elder and the Israeli biotech company Enzymotec have announced the signing of an agreement for launching CardiaBeatTM in the Indian market.

CardiaBeatTM is a conjugated matrix of sterol-omega-3, which exhibits multiple actions for CVD risk reduction in a compact form.

Elder Pharmaceuticals Ltd, based in Mumbai, is one of the fastest growing pharmaceuticals companies and is a segment leader in the therapeutic categories of women health care, nutraceuticals, and wound care. “We are confident that our expertise in handling innovative products, as well as our extensive distribution network covering the entire country, will be the key success factors for CardiaBeatTM in India”. Says Mr. Alok Saxena, Director, Elder Pharmaceuticals, "India is a strategic market for us. The increase in the occurrence of obesity, heart disease, hypertension, and diabetes as well as consumers seeking for innovative self – medicate products, are all important indicators favoring launch of innovative products in India. "We expect that the agreement between Elder and Enzymotec will further establish both companies' leading position in the Indian nutraceutical market." says Dr. Ariel Katz, Enzymotec’s CEO.

Enzymotec is an Israeli biotech company, a developer and manufacturer of bio-functional ingredients for the dietary supplements, functional foods and infant formula markets.
Its key product categories are: SharpPS™ - phosphatidylserine for brain cognitive improvement, InFat™ - structured fat for infant formulas, which mimics mother's milk capacity to increase calcium and energy intake, and CardiaBeat™ - for reducing several CVD-risk factors simultaneously.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.